AI assistant
Acumen Pharmaceuticals, Inc. — Director's Dealing 2025
Jun 5, 2025
34208_dirs_2025-06-05_defd6ab5-23d2-4cb8-a63b-0996034c2f5b.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Acumen Pharmaceuticals, Inc. (ABOS)
CIK: 0001576885
Period of Report: 2025-06-04
Reporting Person: Drapkin Kimberlee C (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-06-04 | Common Stock | A | 12800 | — | Acquired | 12800 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-06-04 | Stock Option (right to buy) | $1.07 | A | 19500 | Acquired | 2035-06-04 | Common Stock (19500) | Direct |
Footnotes
F1: Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in full on the earlier of the first anniversary of the date of grant or the 2026 annual
stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.
F2: The shares subject to the option will vest in full on the earlier of the first anniversary of the date of grant or the 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.